In this article , which was published in the August 15, 2011, issue of Clinical Cancer Research (1), Fig. 4 was incorrectly labeled as Fig. 3. The correct Fig. 3 is shown below. Additionally, on page 5485 of the article, under the section entitled “Pharmacokinetic/pharmacodynamic correlative studies,” it should read “…coupled with a slight decrease in CL/F/dose.” The authors regret this error.
Figure 3.
Variations in pharmacokinetic parameters. A, AUC0–24 h/dose. B, CL/F/dose between baseline (day 1) and steady state (day 28) in Asian nasopharyngeal carcinoma patients.
Figure 3.
Variations in pharmacokinetic parameters. A, AUC0–24 h/dose. B, CL/F/dose between baseline (day 1) and steady state (day 28) in Asian nasopharyngeal carcinoma patients.
References
1.
Lim
W-T
, Ng
Q-S
, Ivy
P
, Leong
S-S
, Singh
O
, Chowbay
B
, et al A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma
. Clin Cancer Res
2011
;17
:5481
–89
.
RSS Feeds
